Dana Pharmaceutical Company (DEDANA) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DEDANA
- Industry
- Pharmaceuticals
- Market
- Iran Fara Bourse
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 | To 1403/09/30 | To 1402/09/30 | To 1401/09/30 | To 1400/09/30 |
|---|---|---|---|---|---|---|
| Operating revenue | 128,239,127 | 42,898,449 | 36,501,350 | 39,449,826 | 22,165,895 | 14,438,190 |
| Cost of operating revenue | -50,706,574 | -21,090,367 | -19,927,769 | -20,691,879 | -9,127,334 | -5,228,250 |
| Gross profit (loss) | 77,532,553 | 21,808,082 | 16,573,581 | 18,757,947 | 13,038,561 | 9,209,940 |
| Selling, general and administrative expenses | -3,421,230 | -1,613,039 | -1,755,487 | -1,015,040 | -760,223 | -499,766 |
| Other income | 489,499 | 185,026 | 184,816 | 147,756 | 71,494 | 53,753 |
| Other expenses | -230,723 | -73,875 | -264,808 | -68,092 | -24,081 | -52,736 |
| Operating profit (loss) | 74,370,099 | 20,306,194 | 14,738,102 | 17,822,571 | 12,325,751 | 8,711,191 |
| Finance costs | -7,616,898 | -4,534,451 | -3,009,826 | -2,276,924 | -1,047,585 | -650,325 |
| Other non-operating income and expenses | 272,412 | 64,168 | 207,959 | 28,361 | 44,315 | 6,168 |
| Profit (loss) from continuing operations before tax | 67,025,613 | 15,835,911 | 11,936,235 | 15,574,008 | 11,322,481 | 8,067,034 |
| Current year tax | -13,405,123 | -3,167,182 | -1,645,806 | -3,893,501 | -2,823,507 | -2,016,759 |
| Net profit (loss) from continuing operations | 53,620,490 | 12,668,729 | 10,290,429 | 11,680,507 | 8,498,974 | 6,050,275 |
| Net profit (loss) | 53,620,490 | 12,668,729 | 10,290,429 | 11,680,507 | 8,498,974 | 6,050,275 |
| Net earnings (loss) per share, rials | 3,724 rials | 1,760 rials | 1,430 rials | 4,867 rials | 3,541 rials | 2,521 rials |
| Capital | 14,400,000 | 7,200,000 | 7,200,000 | 2,400,000 | 2,400,000 | 2,400,000 |
Reporting periods
45 periods are on file for this report, from the period ending 1395/12/30 to the period ending 1405/06/31.